clinical trial · NCT06235086
A Study of TG103 Injection Combined With Metformin in Treatment of Type 2 Diabetes Mellitus
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.·phase3·completed·n = 632
Type 2 Diabetes MellitusTG103Dulaglutide
brief summary
This is a randomized, open-label, dulaglutide-controlled, multicenter Phase 3 trial to evaluate the efficacy, safety, and immunogenicity of different doses of TG103 injection in combination with metformin in subjects with type 2 diabetes with poor glycemic control treated with metformin monotherapy.
started
Apr 8, 2024
primary completion
Feb 3, 2026
completion
Feb 3, 2026
last updated
Apr 3, 2026
official title
A Multicenter, Randomized, Open-label, Controlled Phase 3 Trial of TG103 Injection in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol